Conversely, therapeutic inhibition of NaCT in the liver is a target to improve metabolic diseases, including non-alcoholic fatty liver disease, obesity, and insulin resistance. The gene discussed is SLC13A5; the disease is metabolic dysfunction-associated steatotic liver disease.